Related Experiment Videos
Targeting gene therapy vectors to CNS malignancies
M A Spear1, U Herrlinger, N Rainov
1Department of Neurology, Massachusetts General Hospital & Harvard Medical School, Charlestown 02129, USA.
Abstract:
Gene therapy offers significant advantages to the field of oncology with the addition of specifically and uniquely engineered mechanisms of halting malignant proliferation through cytotoxicity or reproductive arrest. To confer a true benefit to the therapeutic ratio (the relative toxicity to tumor compared to normal tissue) a vector or the transgene it carries must selectively affect or access tumor cells. Beyond the selective toxicities of many transgene products, which frequently parallel that of contemporary chemotherapeutic agents, lies the potential utility of targeting the vector. This review presents an overview of current and potential methods for designing vectors targeted to CNS malignancies through selective delivery, cell entry, transport or transcriptional regulation. The topic of delivery encompasses physical and pharmaceutic means of increasing the relative exposure of tumors to vector. Cell entry based methodologies are founded on increasing relative uptake of vector through the chemical or recombinant addition of ligand and antibody domains which selectively bind receptors expressed on target cells. Targeted transport involves the potential for using cells to selectively carry vectors or transgenes into tumors. Finally, promoter and enhancer systems are discussed which have potential for selectivity activating transcription to produce targeted transgene expression or vector propagation.
Insights
Gene therapy advances oncology by engineering mechanisms to halt cancer growth. This review explores targeted vector design for improved cancer treatment and reduced toxicity.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Gene therapy offers novel mechanisms for halting malignant proliferation via cytotoxicity or reproductive arrest.
- A critical challenge is achieving selective tumor targeting to enhance the therapeutic ratio (tumor toxicity vs. normal tissue toxicity).
Purpose of the Study:
- To review current and potential strategies for designing vectors specifically targeted to Central Nervous System (CNS) malignancies.
- To explore methods for enhancing vector selectivity through delivery, cell entry, transport, and transcriptional regulation.
Main Methods:
- Review of physical and pharmaceutical methods for increasing vector exposure to tumors (delivery).
- Analysis of ligand and antibody-mediated cell entry strategies targeting tumor-specific receptors.
- Discussion of cell-mediated targeted transport and promoter/enhancer systems for selective transgene expression.
Main Results:
- Multiple vector targeting strategies are under development to improve selectivity for CNS malignancies.
- Targeting can be achieved at the vector delivery, cell entry, intracellular transport, and transcriptional activation levels.
- Selective targeting aims to increase therapeutic efficacy while minimizing off-target toxicity.
Conclusions:
- Targeted vector design is crucial for realizing the full potential of gene therapy in oncology, particularly for CNS tumors.
- A multi-pronged approach combining selective delivery, cell entry, transport, and transcriptional control can optimize therapeutic outcomes.